Related Experiment Video
Updated: Jul 7, 2026
11:49
Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level
Published on: November 17, 2013
9.1K
The Michigan Collaborative for Type 2 Diabetes (MCT2D): Development and implementation of a statewide collaborative
Lauren Oshman1, Neha Bhomia2, Heidi L Diez2
1University of Michigan, Ann Arbor, MI, USA. laoshman@med.umich.edu.
BMC Health Services Research
|October 17, 2024
Summary
The Michigan Collaborative for Type 2 Diabetes (MCT2D) is improving care for type 2 diabetes (T2D) by implementing guideline-recommended treatments. This statewide initiative engages numerous physician practices to enhance patient outcomes and reduce healthcare costs.
Area of Science:
- Population health
- Quality improvement initiatives
- Endocrinology and primary care
Background:
- Type 2 Diabetes (T2D) is a widespread chronic disease linked to cardiorenal complications and mortality.
- A significant gap exists in adherence to American Diabetes Association clinical practice guidelines for T2D care.
- There is a critical need for effective strategies to improve the implementation of guideline-concordant T2D care.
Purpose of the Study:
- To establish a statewide collaborative quality initiative (CQI) to enhance T2D care across Michigan.
- To implement evidence-based practices for improving cardiorenal outcomes in T2D patients.
- To support the adoption of continuous glucose monitoring and lower carbohydrate eating patterns.
Main Methods:
- The Michigan Collaborative for Type 2 Diabetes (MCT2D) developed a learning health system engaging physician organizations and practices.
- Initiatives focused on guideline-directed pharmacotherapy, continuous glucose monitoring, and dietary patterns.
- Recruited 28 physician organizations with 336 practices and 1357 physicians between 2021-2022.
Main Results:
- Baseline data from 96,140 individuals with T2D were collected in January 2022.
- 66.3% of patients had an HbA1c ≤ 7.0%, while 14.9% had an HbA1c ≥ 8.0%.
- 64.8% of patients had a Body Mass Index (BMI) ≥ 30.0, indicating obesity.
Conclusions:
- MCT2D successfully organized a statewide collaborative to engage a large and diverse group of healthcare providers.
- The initiative presents a promising model for accelerating guideline-concordant care adoption for T2D nationally.
- Future efforts will target reducing diabetes-related comorbidities, healthcare costs, and T2D prevention.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...